GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hanall Biopharma Co 009420.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

37,100

+3.92%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩155.18bn

FY2016FY2025

Net income

−₩5.56bn

FY2016FY2025

Free cash flow

−₩16.46bn

FY2016FY2025

Shareholders' equity

₩161.68bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩155.18bn₩138.94bn₩134.91bn₩110.00bn₩101.59bn₩88.60bn₩108.45bn₩91.84bn₩84.23bn₩82.88bn
Gross profit₩80.86bn₩73.31bn₩75.17bn₩61.97bn₩60.33bn₩50.65bn₩62.78bn₩49.03bn₩42.68bn₩38.50bn
Research and development₩19.31bn₩19.99bn₩23.94bn₩16.50bn₩10.46bn₩9.32bn₩10.05bn₩10.54bn₩9.79bn₩9.00bn
Operating income−₩915.8m₩230.5m₩2.21bn₩1.51bn₩10.10bn₩5.94bn₩17.09bn₩5.47bn₩3.54bn₩285.4m
Net income−₩5.56bn−₩1.80bn₩3.51bn₩251.5m₩8.90bn₩19.76bn₩19.17bn₩3.30bn₩5.81bn₩2.03bn
Diluted earnings per share-108.63-35.2768.564.91173.83386.20374.6764.48113.5939.70

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩225.22bn₩212.88bn₩239.75bn₩213.45bn₩198.48bn₩220.13bn₩191.38bn₩162.30bn₩168.70bn₩124.73bn
Total liabilities₩63.54bn₩44.53bn₩53.53bn₩45.19bn₩34.99bn₩38.86bn₩50.97bn₩45.39bn₩57.50bn₩20.37bn
Debt₩15.00bn—————————
Shareholders' equity₩161.68bn₩168.35bn₩186.22bn₩168.26bn₩163.49bn₩181.27bn₩140.42bn₩116.92bn₩111.20bn₩104.36bn
Shares outstanding51m51m51m51m51m51m51m51m51m51m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩2.34bn₩9.36bn₩29.64bn₩25.20bn₩839.9m₩929.3m₩20.49bn−₩2.99bn₩42.14bn₩3.95bn
Capital spending−₩14.12bn−₩23.07bn−₩9.20bn−₩2.83bn−₩4.61bn−₩2.56bn−₩2.12bn−₩1.92bn−₩1.73bn−₩4.03bn
Free cash flow−₩16.46bn−₩13.71bn₩20.45bn₩22.37bn−₩3.77bn−₩1.63bn₩18.37bn−₩4.91bn₩40.41bn−₩81.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩44.28bn₩40.03bn₩37.55bn₩40.80bn₩40.68bn₩36.15bn₩36.42bn₩36.84bn
Gross profit₩24.78bn₩21.33bn₩18.66bn₩21.05bn₩21.94bn₩19.21bn₩19.01bn₩19.80bn
Operating income₩5.60bn₩838.7m—₩348.9m₩1.15bn−₩394.5m₩2.74bn₩430.2m
Net income−₩19.23bn₩275.0m−₩6.25bn₩299.0m₩598.8m−₩207.5m₩1.62bn₩221.9m
Diluted earnings per share-375.735.37-122.115.8411.70-4.0531.664.34
Cash from operations−₩6.66bn₩2.46bn−₩12.68bn₩7.34bn₩2.14bn₩850.0m₩3.53bn₩7.26bn
Capital spending−₩2.02bn−₩3.28bn−₩3.50bn−₩3.27bn−₩3.59bn−₩3.76bn−₩6.11bn−₩5.79bn
Free cash flow−₩8.68bn−₩824.0m−₩16.17bn₩4.07bn−₩1.45bn−₩2.91bn−₩2.58bn₩1.48bn
Total assets₩240.51bn₩243.83bn₩225.22bn₩201.82bn₩190.69bn₩195.72bn₩212.88bn₩212.92bn
Debt₩15.00bn₩15.00bn₩15.00bn—————
Shareholders' equity₩161.63bn₩162.36bn₩161.68bn₩157.65bn₩156.11bn₩159.30bn₩168.35bn₩171.36bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.2%11.9%6.8%
Operating income——-14.3%
Net income——-2.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin52.4%54.0%55.2%53.7%
Operating margin-0.2%0.6%2.6%3.5%
Net margin-2.5%-0.7%3.4%4.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-402.8-1095.9——121.197.196.9—214.8331.2
Price to sales14.414.216.88.310.621.717.120.214.88.1

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 27 Dec 2006.

FY2007FY2006FY2005FY2004FY2003FY2002FY2001FY2000
Paid in the year10.005.0020.0025.0025.0050.0040.0030.00
  • 10-for-1 split · 10 May 2006
  • 1.02-for-1 split · 3 Jan 1996
  • 1.02-for-1 split · 3 Jan 1995
  • 1.245-for-1 split · 24 May 1994
  • 1.03-for-1 split · 3 Jan 1994
  • 1.04-for-1 split · 4 Jan 1993

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.